

Non-Tyrosine Kinase Inhibitors-EMEA Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/N530F216D41EN.html>

Date: February 2018

Pages: 147

Price: US\$ 3,480.00 (Single User License)

ID: N530F216D41EN

Abstracts

Report Summary

Non-Tyrosine Kinase Inhibitors-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Non-Tyrosine Kinase Inhibitors industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole EMEA and Regional Market Size of Non-Tyrosine Kinase Inhibitors 2013-2017, and development forecast 2018-2023

Main market players of Non-Tyrosine Kinase Inhibitors in EMEA, with company and product introduction, position in the Non-Tyrosine Kinase Inhibitors market

Market status and development trend of Non-Tyrosine Kinase Inhibitors by types and applications

Cost and profit status of Non-Tyrosine Kinase Inhibitors, and marketing status

Market growth drivers and challenges

The report segments the EMEA Non-Tyrosine Kinase Inhibitors market as:

EMEA Non-Tyrosine Kinase Inhibitors Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Europe

Middle East

Africa

EMEA Non-Tyrosine Kinase Inhibitors Market: Product Type Segment Analysis
(Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

mTOR Inhibitors
RAF/MEK Inhibitors
CDK Inhibitors

EMEA Non-Tyrosine Kinase Inhibitors Market: Application Segment Analysis
(Consumption Volume and Market Share 2013-2023; Downstream Customers and
Market Analysis)

Liver Cancer
Respiratory Cancer
Brain Cancer
Others

EMEA Non-Tyrosine Kinase Inhibitors Market: Players Segment Analysis (Company
and Product introduction, Non-Tyrosine Kinase Inhibitors Sales Volume, Revenue, Price
and Gross Margin):

Roche
Eli Lilly
Novartis
Array BioPharma
Nerviano Medical Sciences
Pfizer
Merck KGaA
Astex Pharmaceuticals
Cyclacel Pharmaceuticals
Daiichi Sankyo
Onconova Therapeutics
AstraZeneca
GlaxoSmithKline (GSK)
Carna Biosciences
Celgene Corporation
Eternity Bioscience
Jasco Pharmaceuticals

In a word, the report provides detailed statistics and analysis on the state of the

industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF NON-TYROSINE KINASE INHIBITORS

- 1.1 Definition of Non-Tyrosine Kinase Inhibitors in This Report
- 1.2 Commercial Types of Non-Tyrosine Kinase Inhibitors
 - 1.2.1 mTOR Inhibitors
 - 1.2.2 RAF/MEK Inhibitors
 - 1.2.3 CDK Inhibitors
- 1.3 Downstream Application of Non-Tyrosine Kinase Inhibitors
 - 1.3.1 Liver Cancer
 - 1.3.2 Respiratory Cancer
 - 1.3.3 Brain Cancer
 - 1.3.4 Others
- 1.4 Development History of Non-Tyrosine Kinase Inhibitors
- 1.5 Market Status and Trend of Non-Tyrosine Kinase Inhibitors 2013-2023
 - 1.5.1 EMEA Non-Tyrosine Kinase Inhibitors Market Status and Trend 2013-2023
 - 1.5.2 Regional Non-Tyrosine Kinase Inhibitors Market Status and Trend 2013-2023

CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Non-Tyrosine Kinase Inhibitors in EMEA 2013-2017
- 2.2 Consumption Market of Non-Tyrosine Kinase Inhibitors in EMEA by Regions
 - 2.2.1 Consumption Volume of Non-Tyrosine Kinase Inhibitors in EMEA by Regions
 - 2.2.2 Revenue of Non-Tyrosine Kinase Inhibitors in EMEA by Regions
- 2.3 Market Analysis of Non-Tyrosine Kinase Inhibitors in EMEA by Regions
 - 2.3.1 Market Analysis of Non-Tyrosine Kinase Inhibitors in Europe 2013-2017
 - 2.3.2 Market Analysis of Non-Tyrosine Kinase Inhibitors in Middle East 2013-2017
 - 2.3.3 Market Analysis of Non-Tyrosine Kinase Inhibitors in Africa 2013-2017
- 2.4 Market Development Forecast of Non-Tyrosine Kinase Inhibitors in EMEA 2018-2023
 - 2.4.1 Market Development Forecast of Non-Tyrosine Kinase Inhibitors in EMEA 2018-2023
 - 2.4.2 Market Development Forecast of Non-Tyrosine Kinase Inhibitors by Regions 2018-2023

CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES

- 3.1 Whole EMEA Market Status by Types

- 3.1.1 Consumption Volume of Non-Tyrosine Kinase Inhibitors in EMEA by Types
- 3.1.2 Revenue of Non-Tyrosine Kinase Inhibitors in EMEA by Types
- 3.2 EMEA Market Status by Types in Major Countries
 - 3.2.1 Market Status by Types in Europe
 - 3.2.2 Market Status by Types in Middle East
 - 3.2.3 Market Status by Types in Africa
- 3.3 Market Forecast of Non-Tyrosine Kinase Inhibitors in EMEA by Types

CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Demand Volume of Non-Tyrosine Kinase Inhibitors in EMEA by Downstream Industry
- 4.2 Demand Volume of Non-Tyrosine Kinase Inhibitors by Downstream Industry in Major Countries
 - 4.2.1 Demand Volume of Non-Tyrosine Kinase Inhibitors by Downstream Industry in Europe
 - 4.2.2 Demand Volume of Non-Tyrosine Kinase Inhibitors by Downstream Industry in Middle East
 - 4.2.3 Demand Volume of Non-Tyrosine Kinase Inhibitors by Downstream Industry in Africa
- 4.3 Market Forecast of Non-Tyrosine Kinase Inhibitors in EMEA by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF NON-TYROSINE KINASE INHIBITORS

- 5.1 EMEA Economy Situation and Trend Overview
- 5.2 Non-Tyrosine Kinase Inhibitors Downstream Industry Situation and Trend Overview

CHAPTER 6 NON-TYROSINE KINASE INHIBITORS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA

- 6.1 Sales Volume of Non-Tyrosine Kinase Inhibitors in EMEA by Major Players
- 6.2 Revenue of Non-Tyrosine Kinase Inhibitors in EMEA by Major Players
- 6.3 Basic Information of Non-Tyrosine Kinase Inhibitors by Major Players
 - 6.3.1 Headquarters Location and Established Time of Non-Tyrosine Kinase Inhibitors Major Players
 - 6.3.2 Employees and Revenue Level of Non-Tyrosine Kinase Inhibitors Major Players

- 6.4 Market Competition News and Trend
 - 6.4.1 Merger, Consolidation or Acquisition News
 - 6.4.2 Investment or Disinvestment News
 - 6.4.3 New Product Development and Launch

CHAPTER 7 NON-TYROSINE KINASE INHIBITORS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 Roche

- 7.1.1 Company profile
- 7.1.2 Representative Non-Tyrosine Kinase Inhibitors Product
- 7.1.3 Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin of Roche

7.2 Eli Lilly

- 7.2.1 Company profile
- 7.2.2 Representative Non-Tyrosine Kinase Inhibitors Product
- 7.2.3 Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin of Eli Lilly

7.3 Novartis

- 7.3.1 Company profile
- 7.3.2 Representative Non-Tyrosine Kinase Inhibitors Product
- 7.3.3 Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin of Novartis

7.4 Array BioPharma

- 7.4.1 Company profile
- 7.4.2 Representative Non-Tyrosine Kinase Inhibitors Product
- 7.4.3 Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin of Array BioPharma

7.5 Nerviano Medical Sciences

- 7.5.1 Company profile
- 7.5.2 Representative Non-Tyrosine Kinase Inhibitors Product
- 7.5.3 Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin of Nerviano Medical Sciences

7.6 Pfizer

- 7.6.1 Company profile
- 7.6.2 Representative Non-Tyrosine Kinase Inhibitors Product
- 7.6.3 Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin of Pfizer

7.7 Merck KGaA

- 7.7.1 Company profile
- 7.7.2 Representative Non-Tyrosine Kinase Inhibitors Product
- 7.7.3 Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin of Merck KGaA
- 7.8 Astex Pharmaceuticals
 - 7.8.1 Company profile
 - 7.8.2 Representative Non-Tyrosine Kinase Inhibitors Product
 - 7.8.3 Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin of Astex Pharmaceuticals
- 7.9 Cyclacel Pharmaceuticals
 - 7.9.1 Company profile
 - 7.9.2 Representative Non-Tyrosine Kinase Inhibitors Product
 - 7.9.3 Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin of Cyclacel Pharmaceuticals
- 7.10 Daiichi Sankyo
 - 7.10.1 Company profile
 - 7.10.2 Representative Non-Tyrosine Kinase Inhibitors Product
 - 7.10.3 Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin of Daiichi Sankyo
- 7.11 Onconova Therapeutics
 - 7.11.1 Company profile
 - 7.11.2 Representative Non-Tyrosine Kinase Inhibitors Product
 - 7.11.3 Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin of Onconova Therapeutics
- 7.12 AstraZeneca
 - 7.12.1 Company profile
 - 7.12.2 Representative Non-Tyrosine Kinase Inhibitors Product
 - 7.12.3 Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin of AstraZeneca
- 7.13 GlaxoSmithKline (GSK)
 - 7.13.1 Company profile
 - 7.13.2 Representative Non-Tyrosine Kinase Inhibitors Product
 - 7.13.3 Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin of GlaxoSmithKline (GSK)
- 7.14 Carna Biosciences
 - 7.14.1 Company profile
 - 7.14.2 Representative Non-Tyrosine Kinase Inhibitors Product
 - 7.14.3 Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin of Carna Biosciences

7.15 Celgene Corporation

7.15.1 Company profile

7.15.2 Representative Non-Tyrosine Kinase Inhibitors Product

7.15.3 Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin of Celgene Corporation

7.16 Eternity Bioscience

7.17 Jasco Pharmaceuticals

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF NON-TYROSINE KINASE INHIBITORS

8.1 Industry Chain of Non-Tyrosine Kinase Inhibitors

8.2 Upstream Market and Representative Companies Analysis

8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF NON-TYROSINE KINASE INHIBITORS

9.1 Cost Structure Analysis of Non-Tyrosine Kinase Inhibitors

9.2 Raw Materials Cost Analysis of Non-Tyrosine Kinase Inhibitors

9.3 Labor Cost Analysis of Non-Tyrosine Kinase Inhibitors

9.4 Manufacturing Expenses Analysis of Non-Tyrosine Kinase Inhibitors

CHAPTER 10 MARKETING STATUS ANALYSIS OF NON-TYROSINE KINASE INHIBITORS

10.1 Marketing Channel

10.1.1 Direct Marketing

10.1.2 Indirect Marketing

10.1.3 Marketing Channel Development Trend

10.2 Market Positioning

10.2.1 Pricing Strategy

10.2.2 Brand Strategy

10.2.3 Target Client

10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

12.1 Methodology/Research Approach

12.1.1 Research Programs/Design

12.1.2 Market Size Estimation

12.1.3 Market Breakdown and Data Triangulation

12.2 Data Source

12.2.1 Secondary Sources

12.2.2 Primary Sources

12.3 Reference

I would like to order

Product name: Non-Tyrosine Kinase Inhibitors-EMEA Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/N530F216D41EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N530F216D41EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970